Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF
Other DNA/RNA Synthesis Inhibitors	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 EED226 BMH-21 Carmofur Triapine (3-AP) YK-4-279 Halofuginone

Solubility

In vitro
Batch:

DMSO : 60 mg/mL (201.83 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 3 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	saline Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.000mg/ml (10.09mM)	Taking the 1 mL working solution as an example, add 3 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	297.27	Formula	C₁₁H₁₅N₅O₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	121032-29-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	506U78,Arranon			SMILES	COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Features	Nelarabine is rapidly converted into ara-G through demethoxylation by adenosine deaminase.
Targets/IC₅₀/Ki	DNA synthesis (PER-255 cells) 67 nM DNA synthesis (HSB2 cells) 0.44 μM DNA synthesis (ALL-SIL cells) 1.24 μM DNA synthesis (JURKAT cells) 2.15 μM
In vitro	The IC50 of Nelarabine is 25-fold and 113-fold higher than ARAC in T- and B-lineage, respectively. T-ALL cells are eightfold more sensitive to this compound than B-lineage but there is considerable overlap. The efficacy of this chemical in T-lineage and B-lineage cell lines is 25-fold and 113-fold less than ARAC, respectively. It acts by inhibiting DNA synthesis and inducing apoptosis in susceptible cells. This agent demonstrated significant antineoplastic activity with acceptable toxicity.
In vivo	The Nelarabine plasma AUC is 2.82 mM minutes and the ara-G plasma AUC is 20 mM minutes. The terminal half-life of this compound in plasma is 25 min, clearance is 42 mL/minutes/kg, and central volume of distribution is 1.1 L/kg. The terminal half-life of ara-G in plasma is 182 minutes and the central volume of distribution is 1.4 L/kg. In CSF the terminal half-life of this chemical is 77 minutes and of ara-G is 232 minutes. The AUCcsf:AUCplasma is 29 % for this agent and 23 % for ara-G. This compound and ara-G do not accumulate with daily infusions because of their relatively short half-lives.
References	[1] https://pubmed.ncbi.nlm.nih.gov/17391490/ [2] https://pubmed.ncbi.nlm.nih.gov/16925505/ [3] https://pubmed.ncbi.nlm.nih.gov/17344466/ [4] https://pubmed.ncbi.nlm.nih.gov/16953392/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-30)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07072585	NOT_YET_RECRUITING	Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma	Children's Oncology Group	2026-08-28	PHASE2; PHASE3
NCT07294677	RECRUITING	Leukemia; Lymphoma	University of Chicago	2026-03-17	PHASE1; PHASE2
NCT06390319	RECRUITING	T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoma; Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	2024-12-27	PHASE2
NCT03020030	ACTIVE_NOT_RECRUITING	Acute Lymphoblastic Leukemia, Pediatric	Dana-Farber Cancer Institute	2017-03-03	PHASE3
NCT00501826	RECRUITING	T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma	M.D. Anderson Cancer Center	2007-07-11	PHASE2
NCT03117751	ACTIVE_NOT_RECRUITING	Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma	St. Jude Children's Research Hospital	2017-03-29	PHASE2; PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Nelarabine DNA/RNA Synthesis inhibitor

Chemical Structure

Molecular Weight: 297.27